# Steven Larson

List of Publications by Year
in descending order



| 232 | 19,982 | 7096 78 | 11939 134 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 242 | 242 | 242 | 17939 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2022, 21, 125-137. | 4.1 | 5 |
| 2 | Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , . | 1.9 | 1 |
| 3 | Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 2022, 28, 2030-2037. | 7.0 | 21 |
| 4 | A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research, 2021, 27, 532-541. | 7.0 | 19 |
| 5 | IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamabâ€"pharmacokinetic modeling to optimize therapeutic index. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1166-1177. | 6.4 | 9 |
| 6 | Î³-Tocotrienolâ€"Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. Journal of Nuclear Medicine, 2021, 62, 584-590. | 5.0 | 6 |
| 7 | PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060. | 7.0 | 13 |
| 8 | A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651. | 6.4 | 26 |
| 9 | Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056. | 5.0 | 19 |
| 10 | Acid-Sphingomyelinase Triggered Fluorescently Labeled Sphingomyelin Containing Liposomes in Tumor Diagnosis after Radiation-Induced Stress. International Journal of Molecular Sciences, 2021, 22, 3864. | 4.1 | 3 |
| 11 | Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654. | 3.6 | 6 |
| 12 | Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I. EJNMMI Physics, 2021, 8, 50. | 2.7 | 1 |
| 13 | Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG). Molecular Imaging and Biology, 2020, 22, 358-366. | 2.6 | 8 |
| 14 | An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate Chemistry, 2020, 31, 501-506. | 3.6 | 16 |
| 15 | Alpha radioimmunotherapy using <sup>225</sup>Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics, 2020, 10, 11359-11375. | 10.0 | 26 |
| 16 | CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773. | 2.8 | 7 |
| 17 | Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296. | 2.3 | 16 |
| 18 | First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clinical Cancer Research, 2020, 26, 5178-5187. | 7.0 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181. | 7.1 | 16 |
| 20 | First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587. | 5.0 | 5 |
| 21 | Gallagherâ€™s Principle of Metabolic Trapping (perspective on â€œMetabolic Trapping as a Principle of) Tj ETQq1 1 0.784314 rgBT /Ov<br>2020, 61, 74S-82S. | 5.0 | 2 |
| 22 | Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine, 2019, 60, 1794-1801. | 5.0 | 29 |
| 23 | Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell, 2019, 36, 559-573.e7. | 16.8 | 40 |
| 24 | Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular Pharmaceutics, 2019, 16, 3083-3090. | 4.6 | 26 |
| 25 | Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using<sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523. | 5.0 | 38 |
| 26 | Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prostate Cancer and Prostatic Diseases, 2019, 22, 522-530. | 3.9 | 15 |
| 27 | Thyroid Cancer Bone Metastasis. Clinical Nuclear Medicine, 2019, 44, e465-e471. | 1.3 | 22 |
| 28 | Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1417-1428. | 3.6 | 165 |
| 29 | EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209. | 9.4 | 115 |
| 30 | Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891. | 7.0 | 21 |
| 31 | Copper-64 trastuzumab PET imaging: a reproducibility study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 191-198. | 0.7 | 21 |
| 32 | ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Molecular Pharmaceutics, 2018, 15, 2133-2141. | 4.6 | 4 |
| 33 | Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629. | 12.8 | 37 |
| 34 | Reproducibility and Repeatability of Semiquantitative <sup>18</sup>F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 1516-1523. | 5.0 | 20 |
| 35 | Pharmacokinetics, Biodistribution, and Radiation Dosimetry for <sup>89</sup>Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of Nuclear Medicine, 2018, 59, 161-166. | 5.0 | 96 |
| 36 | Biodistribution and Dosimetry of <sup>18</sup>F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Journal of Nuclear Medicine, 2018, 59, 147-153. | 5.0 | 96 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A phase II study of radioimmunotherapy with intraventricular <sup>131</sup>Iâ€3F8 for medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e26754. | 1.5 | 46 |
| 38 | Positron Emission Tomography/Computed Tomographyâ€"Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217. | 7.1 | 93 |
| 39 | Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics, 2018, 8, 5106-5125. | 10.0 | 32 |
| 40 | TMSOTf assisted synthesis of 2â€™-deoxy-2â€™-[18F]fluoro-Î²-D-arabinofuranosylcytosine ([18F]FAC). PLoS ONE, 2018, 13, e0196784. | 2.5 | 3 |
| 41 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research, 2018, 8, 20. | 2.5 | 17 |
| 42 | Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900. | 5.0 | 36 |
| 43 | Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncology, The, 2018, 19, 1040-1050. | 10.7 | 201 |
| 44 | Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular Systems Biology, 2017, 13, 914. | 7.2 | 73 |
| 45 | Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951. | 2.6 | 7 |
| 46 | Theranostic Concepts: More Than Just a Fashion Trendâ€"Introduction and Overview. Journal of Nuclear Medicine, 2017, 58, 1S-2S. | 5.0 | 36 |
| 47 | Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 1735-1742. | 5.0 | 36 |
| 48 | Cancer Biology of Molecular Imaging. , 2017, , 3-34. | | 0 |
| 49 | Quantitative Assessment of Early [<sup>18</sup>F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. Journal of Clinical Oncology, 2017, 35, 2829-2837. | 1.6 | 52 |
| 50 | In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget, 2017, 8, 65917-65931. | 1.8 | 17 |
| 51 | Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy, 2017, 26, 80-86. | 0.7 | 8 |
| 52 | Loss of a pioneer: Hussein Abdel-Dayem, MD 1934-2017. World Journal of Nuclear Medicine, 2017, 16, 255. | 0.5 | 0 |
| 53 | Radiosynthesis of the iodineâ€124 labeled Hsp90 inhibitor PUâ€H71. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 129-132. | 1.0 | 17 |
| 54 | Internalization of secreted antigenâ€"targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167. | 12.4 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptorâ€“Axis Imaging. Journal of Nuclear Medicine, 2016, 57, 73S-78S. | 5.0 | 16 |
| 56 | The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401. | 27.8 | 233 |
| 57 | First-in-Human Imaging with <sup>89</sup>Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864. | 5.0 | 116 |
| 58 | Copper-64 labeled liposomes for imaging bone marrow. Nuclear Medicine and Biology, 2016, 43, 781-787. | 0.6 | 25 |
| 59 | A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. Journal of Nuclear Medicine, 2016, 57, 1865-1871. | 5.0 | 31 |
| 60 | Repeatability of Quantitative <sup>18</sup>F-NaF PET: A Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 1872-1879. | 5.0 | 62 |
| 61 | Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Research, 2016, 6, 23. | 2.5 | 37 |
| 62 | Arsenic Trioxide as a Radiation Sensitizer for <sup>131</sup>I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of Nuclear Medicine, 2016, 57, 231-237. | 5.0 | 17 |
| 63 | Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 925-937. | 6.4 | 38 |
| 64 | Prospective Study of 3â€²-Deoxy-3â€²-<sup>18</sup>F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of Nuclear Medicine, 2016, 57, 728-734. | 5.0 | 41 |
| 65 | Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7. | 2.5 | 32 |
| 66 | EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan. Journal of Nuclear Medicine, 2016, 57, 5-6. | 5.0 | 7 |
| 67 | Cancer Biology of Molecular Imaging. , 2016, , 1-31. | | 0 |
| 68 | Everolimus combined with gefitinib in patients with metastatic castrationâ€resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, 121, 3853-3861. | 4.1 | 27 |
| 69 | Radioimmunotherapy of human tumours. Nature Reviews Cancer, 2015, 15, 347-360. | 28.4 | 382 |
| 70 | Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. Journal of Biological Chemistry, 2015, 290, 30018-30029. | 3.4 | 84 |
| 71 | Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363. | 1.6 | 120 |
| 72 | Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. Nuclear Medicine and Biology, 2015, 42, 375-380. | 0.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Better use of bone scans in prostate cancer. Nature Reviews Urology, 2015, 12, 190-191. | 3.8 | 3 |
| 74 | A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285. | 7.0 | 163 |
| 75 | Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28. | 2.5 | 63 |
| 76 | PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706. | 6.4 | 13 |
| 77 | 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2093-2105. | 6.4 | 130 |
| 78 | Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149. | 12.4 | 589 |
| 79 | Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nature Communications, 2014, 5, 3097. | 12.8 | 139 |
| 80 | Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology, 2014, 271, 220-229. | 7.3 | 88 |
| 81 | How to assess background activity. Nuclear Medicine Communications, 2014, 35, 316-324. | 1.1 | 14 |
| 82 | Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex. Molecular Cancer Therapeutics, 2014, 13, 1803-1812. | 4.1 | 52 |
| 83 | PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nuclear Medicine and Biology, 2014, 41, 410-418. | 0.6 | 33 |
| 84 | Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: Î± Therapy with <sup>223</sup>Ra-Dichloride. Journal of Nuclear Medicine, 2014, 55, 268-274. | 5.0 | 86 |
| 85 | Evaluation of Glycodendron and Synthetically Modified Dextran Clearing Agents for Multistep Targeting of Radioisotopes for Molecular Imaging and Radioimmunotherapy. Molecular Pharmaceutics, 2014, 11, 400-416. | 4.6 | 8 |
| 86 | Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 985-994. | 6.4 | 65 |
| 87 | A Prospective Pilot Study of <sup>89</sup> Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2014, 191, 1439-1445. | 0.4 | 73 |
| 88 | Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. Seminars in Oncology, 2013, 40, 375-392. | 2.2 | 34 |
| 89 | Tumor biology as a basis for molecular targeting in cancer. Clinical and Translational Imaging, 2013, 1, 397-406. | 2.1 | 2 |
| 90 | Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3525-3530. | 1.6 | 223 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial. Journal of Clinical Oncology, 2013, 31, 187-194. | 1.6 | 201 |
| 92 | Validation and clinical utility of prostate cancer biomarkers. Nature Reviews Clinical Oncology, 2013, 10, 225-234. | 27.6 | 83 |
| 93 | Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E829-E836. | 3.6 | 108 |
| 94 | Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET. Molecular Imaging and Biology, 2013, 15, 768-775. | 2.6 | 11 |
| 95 | Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1384-1393. | 6.4 | 160 |
| 96 | The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer, Based on Memorial Sloan-Kettering Cancer Center Risk Group Stratification. Thyroid, 2013, 23, 683-694. | 4.5 | 75 |
| 97 | N-Acetylgalactosamino Dendrons as Clearing Agents to Enhance Liver Targeting of Model Antibody-Fusion Protein. Bioconjugate Chemistry, 2013, 24, 2088-2103. | 3.6 | 5 |
| 98 | Split-Dose Technique for FDG PET/CTâ€“guided Percutaneous Ablation: A Method to Facilitate Lesion Targeting and to Provide Immediate Assessment of Treatment Effectiveness. Radiology, 2013, 268, 288-295. | 7.3 | 107 |
| 99 | Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 1697-1702. | 5.0 | 64 |
| 100 | Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?. Annals of Oncology, 2013, 24, 1948-1949. | 1.2 | 3 |
| 101 | Pilot study of 68Ga-DOTA-F(abâ€²)2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165. | 1.1 | 68 |
| 102 | Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Medicine, 2013, 2, 725-733. | 2.8 | 54 |
| 103 | Repetitively dosed docetaxel and <sup>153</sup>samariumâ€EDTMP as an antitumor strategy for metastatic castrationâ€resistant prostate cancer. Cancer, 2013, 119, 3186-3194. | 4.1 | 23 |
| 104 | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8. | 3.3 | 9 |
| 105 | Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.. Journal of Clinical Oncology, 2013, 31, 11076-11076. | 1.6 | 5 |
| 106 | Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 31-31. | 1.6 | 8 |
| 107 | Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen. Cancer Discovery, 2012, 2, 320-327. | 9.4 | 68 |
| 108 | Molecular imaging of prostate cancer. Current Opinion in Urology, 2012, 22, 320-327. | 1.8 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 519-524. | 1.6 | 162 |
| 110 | Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer, 2012, 118, 5454-5462. | 4.1 | 55 |
| 111 | Molecular imaging for personalized cancer care. Molecular Oncology, 2012, 6, 182-195. | 4.6 | 150 |
| 112 | Repeatability of SUV measurements in serial PET. Medical Physics, 2011, 38, 2629-2638. | 3.0 | 26 |
| 113 | Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation, 2011, 121, 4700-4711. | 8.2 | 305 |
| 114 | Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9578-9582. | 7.1 | 268 |
| 115 | Radiofrequency Ablation of Non-Small-Cell Carcinoma of the Lung Under Real-Time FDG PET CT Guidance. CardioVascular and Interventional Radiology, 2011, 34, 182-185. | 2.0 | 30 |
| 116 | Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. Journal of Clinical Investigation, 2011, 121, 2768-2780. | 8.2 | 558 |
| 117 | The Janus Project: The Remaking of Nuclear Medicine and Radiology. Journal of Nuclear Medicine, 2011, 52, 3S-9S. | 5.0 | 17 |
| 118 | <sup>124</sup>I-huA33 Antibody PET of Colorectal Cancer. Journal of Nuclear Medicine, 2011, 52, 1173-1180. | 5.0 | 85 |
| 119 | Developing imaging strategies for castration resistant prostate cancer. Acta OncolÃ³gica, 2011, 50, 39-48. | 1.8 | 48 |
| 120 | Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. Journal of Nuclear Medicine, 2011, 52, 1727-1732. | 5.0 | 46 |
| 121 | Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology, 2011, 7, 818-826. | 8.0 | 240 |
| 122 | <sup>124</sup>I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. Journal of Nuclear Medicine, 2011, 52, 1878-1885. | 5.0 | 47 |
| 123 | Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). Blood, 2011, 118, 768-768. | 1.4 | 27 |
| 124 | Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3154-3159. | 1.6 | 121 |
| 125 | Pharmacokinetic Assessment of the Uptake of 16Î²-<sup>18</sup>F-Fluoro-5Î±-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. Journal of Nuclear Medicine, 2010, 51, 183-192. | 5.0 | 113 |
| 126 | <sup>89</sup>Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo. Journal of Nuclear Medicine, 2010, 51, 1293-1300. | 5.0 | 373 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Global Trends in Hybrid Imaging. Radiology, 2010, 257, 498-506. | 7.3 | 44 |
| 128 | <sup>124</sup>I-Iodopyridopyrimidinone for PET of Abl Kinaseâ€“Expressing Tumors In Vivo. Journal of Nuclear Medicine, 2010, 51, 121-129. | 5.0 | 9 |
| 129 | Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. Clinical Cancer Research, 2010, 16, 6093-6099. | 7.0 | 130 |
| 130 | Sequential Cytarabine and Î±-Particle Immunotherapy with Bismuth-213â€“Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5303-5311. | 7.0 | 234 |
| 131 | <sup>18</sup>F-FDG PET/CT for the Prediction and Detection of Local Recurrence After Radiofrequency Ablation of Malignant Lung Lesions. Journal of Nuclear Medicine, 2010, 51, 1833-1840. | 5.0 | 68 |
| 132 | The Effect of Posttherapy <sup>131</sup>I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2010, 51, 1361-1367. | 5.0 | 102 |
| 133 | Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 2436-2442. | 1.6 | 92 |
| 134 | 2-18F-Fluoropropionic Acid as a PET Imaging Agent for Prostate Cancer. Journal of Nuclear Medicine, 2009, 50, 1709-1714. | 5.0 | 31 |
| 135 | Fluorescent Silica Nanoparticles with Efficient Urinary Excretion for Nanomedicine. Nano Letters, 2009, 9, 442-448. | 9.1 | 441 |
| 136 | An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. Medical Physics, 2009, 36, 4803-4809. | 3.0 | 51 |
| 137 | Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience. Current Pharmaceutical Design, 2009, 15, 950-956. | 1.9 | 7 |
| 138 | New PET tracers for evaluation of solid tumor response to therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 158-66. | 0.7 | 17 |
| 139 | Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTAâ€“MORAb-003. Nuclear Medicine and Biology, 2008, 35, 343-351. | 0.6 | 42 |
| 140 | Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using <sup>111</sup>In-J591: Lesion Detectability and Dosimetric Projections for <sup>90</sup>Y Radioimmunotherapy. Journal of Nuclear Medicine, 2008, 49, 1066-1074. | 5.0 | 76 |
| 141 | Advances in positron emission tomography applications for urologic cancers. Current Opinion in Urology, 2008, 18, 65-70. | 1.8 | 33 |
| 142 | The Future of Molecular Imaging. , 2008, , 693-704. | | 0 |
| 143 | Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2007, 13, 7053-7058. | 7.0 | 608 |
| 144 | Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. Clinical Cancer Research, 2007, 13, 2707-2713. | 7.0 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. Clinical Cancer Research, 2007, 13, 1775-1782. | 7.0 | 198 |
| 146 | 3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Research, 2007, 67, 11463-11469. | 0.9 | 66 |
| 147 | Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncology, The, 2007, 8, 304-310. | 10.7 | 370 |
| 148 | The Role of Iodine-124-Positron Emission Tomography Imaging in the Management of Patients with Thyroid Cancer. PET Clinics, 2007, 2, 313-320. | 3.0 | 12 |
| 149 | Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib. Journal of Medicinal Chemistry, 2007, 50, 5853-5857. | 6.4 | 38 |
| 150 | Improved tumor imaging and therapy via i.v. IgGâ€“mediated time-sequential modulation of neonatal Fc receptor. Journal of Clinical Investigation, 2007, 117, 2422-2430. | 8.2 | 31 |
| 151 | Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 910-910. | 1.4 | 15 |
| 152 | Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. Journal of Nuclear Medicine, 2007, 48, 143-9. | 5.0 | 59 |
| 153 | Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection. Annals of Thoracic Surgery, 2006, 81, 1076-1081. | 1.3 | 118 |
| 154 | Molecular Imaging of EGFR Kinase Activity in Tumors with 124I-Labeled Small Molecular Tracer and Positron Emission Tomography. Molecular Imaging and Biology, 2006, 8, 262-277. | 2.6 | 98 |
| 155 | Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 498-505. | 3.6 | 513 |
| 156 | Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. Translational Medicine Series, 2006, , 291-313. | 0.0 | 0 |
| 157 | Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of Nuclear Medicine, 2006, 47, 793-6. | 5.0 | 136 |
| 158 | Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. Journal of Nuclear Medicine, 2006, 47, 140-9. | 5.0 | 39 |
| 159 | 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. Journal of Nuclear Medicine, 2006, 47, 901-3. | 5.0 | 56 |
| 160 | Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine, 2006, 47, 1587-91. | 5.0 | 127 |
| 161 | 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4761-4769. | 7.0 | 210 |
| 162 | Pilot Trial of Unlabeled and Indium-111â€“Labeled Antiâ€“Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 7454-7461. | 7.0 | 120 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy. Clinical Cancer Research, 2005, 11, 3210-3216. | 7.0 | 122 |
| 164 | Intensity of<sup>18</sup>Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2005, 23, 4643-4651. | 1.6 | 462 |
| 165 | The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985. | 7.0 | 219 |
| 166 | Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nuclear Medicine and Biology, 2005, 32, 313-321. | 0.6 | 14 |
| 167 | A pragmatic perspective on molecular targeted radionuclide therapy. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 1S-3S. | 5.0 | 4 |
| 168 | Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection. Journal of Clinical Oncology, 2004, 22, 3255-3260. | 1.6 | 339 |
| 169 | Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnology, 2004, 22, 701-706. | 17.5 | 288 |
| 170 | Positron emission tomography for prostate, bladder, and renal cancer. Seminars in Nuclear Medicine, 2004, 34, 274-292. | 4.6 | 312 |
| 171 | Positron Emission Tomography/Computerized Tomography Functional Imaging of Esophageal and Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2004, 10, 243-250. | 2.0 | 26 |
| 172 | Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790. | 1.4 | 12 |
| 173 | Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Journal of Nuclear Medicine, 2004, 45, 366-73. | 5.0 | 226 |
| 174 | Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. Journal of Nuclear Medicine, 2004, 45, 867-77. | 5.0 | 41 |
| 175 | The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. Journal of Nuclear Medicine, 2004, 45, 1287-92. | 5.0 | 189 |
| 176 | Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine, 2004, 45, 1366-72. | 5.0 | 196 |
| 177 | PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of Nuclear Medicine, 2004, 45, 1966-71. | 5.0 | 61 |
| 178 | Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplantation, 2003, 32, 549-556. | 2.4 | 102 |
| 179 | Whole Body18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. Journal of Clinical Oncology, 2003, 21, 428-432. | 1.6 | 338 |
| 180 | Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology, 2002, 59, 913-918. | 1.0 | 203 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Positron emission tomography in thyroid cancer management. Seminars in Roentgenology, 2002, 37, 169-174. | 0.6 | 70 |
| 182 | Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-9. | 1.4 | 143 |
| 183 | FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 155-164. | 2.1 | 124 |
| 184 | Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. Journal of Clinical Oncology, 2001, 19, 3397-3405. | 1.6 | 159 |
| 185 | Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 194-196. | 1.0 | 33 |
| 186 | N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230. | 1.0 | 114 |
| 187 | Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology, 2001, 51, 177-180. | 2.4 | 38 |
| 188 | N7: A novel multiâ€modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230. | 1.0 | 1 |
| 189 | Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. Journal of Nuclear Medicine, 2001, 42, 1251-6. | 5.0 | 23 |
| 190 | Targeted radioimmunotherapy for leptomeningeal cancer using131I-3F8. Medical and Pediatric Oncology, 2000, 35, 716-718. | 1.0 | 43 |
| 191 | Enhancing the Uptake of Chemotherapeutic Drugs into Tumors using an â€œArtificial Lymphatic Systemâ€ Annals of Biomedical Engineering, 2000, 28, 556-564. | 2.5 | 6 |
| 192 | Use of PET to monitor the response of lung cancer to radiation treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 861-866. | 6.4 | 108 |
| 193 | Quantitative Imaging of Yttrium-86 with PET The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. Molecular Imaging and Biology, 2000, 3, 85-90. | 0.3 | 50 |
| 194 | â€œArtificial Lymphatic Systemâ€ A New Approach to Reduce Interstitial Hypertension and Increase Blood Flow, pH and pO2in Solid Tumors. Annals of Biomedical Engineering, 2000, 28, 543-555. | 2.5 | 25 |
| 195 | Bone Metastases From Thyroid Carcinoma. Archives of Pathology and Laboratory Medicine, 2000, 124, 1440-1447. | 2.5 | 61 |
| 196 | Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. Journal of Nuclear Medicine, 2000, 41, 1905-12. | 5.0 | 20 |
| 197 | Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 948-948. | 1.6 | 218 |
| 198 | Differential Metabolism and Pharmacokinetics of ?-[1-11C]-Methionine and 2-[18F] Fluoro-2-deoxy-?-glucose (FDG) in Androgen Independent Prostate Cancer. Molecular Imaging and Biology, 1999, 2, 173-181. | 0.3 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion Glycolysis. Molecular Imaging and Biology, 1999, 2, 159-171. | 0.3 | 516 |
| 200 | Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Molecular Imaging and Biology, 1999, 2, 41-46. | 0.3 | 71 |
| 201 | [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2291-2302. | 3.6 | 103 |
| 202 | 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. Journal of Nuclear Medicine, 1999, 40, 1764-8. | 5.0 | 8 |
| 203 | Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. Journal of Nuclear Medicine, 1999, 40, 1935-46. | 5.0 | 129 |
| 204 | A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clinical Cancer Research, 1998, 4, 1765-72. | 7.0 | 168 |
| 205 | Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clinical Cancer Research, 1998, 4, 2729-39. | 7.0 | 118 |
| 206 | Chemical Consequences Resulting from Multi-millicurie Preparation of 6-[<sup>18</sup>F]-Fluoro-6-deoxy-L-ascorbic Acid. Radiochimica Acta, 1997, 77, 87-89. | 1.2 | 3 |
| 207 | Determination of the elemental distribution in cigarette components and smoke by instrumental neutron activation analysis. Journal of Radioanalytical and Nuclear Chemistry, 1997, 217, 77-82. | 1.5 | 43 |
| 208 | Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. , 1997, 80, 1507-1512. | | 37 |
| 209 | Single chain antigen binding protein (sFv CC49). Cancer, 1997, 80, 2458-2468. | 4.1 | 52 |
| 210 | Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer, 1997, 80, 2505-2509. | 4.1 | 377 |
| 211 | Single chain antigen binding protein (sFv CC49). Cancer, 1997, 80, 2458-2468. | 4.1 | 8 |
| 212 | Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer, 1997, 80, 2505-2509. | 4.1 | 174 |
| 213 | Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. Nuclear Medicine and Biology, 1996, 23, 1-8. | 0.6 | 25 |
| 214 | Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nuclear Medicine and Biology, 1996, 23, 693-697. | 0.6 | 140 |
| 215 | Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 145-149. | 2.1 | 49 |
| 216 | Quantitative imaging of iodine-124 with PET. Journal of Nuclear Medicine, 1996, 37, 1557-62. | 5.0 | 130 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Chemically Treated Activated Carbon Cloths for Removal of Volatile Organic Carbons from Gas Streams: Evidence for Enhanced Physical Adsorption. Environmental Science & Technology, 1995, 29, 1876-1880. | 10.0 | 81 |
| 218 | Evaluation of Elemental Cadmium as a Marker for Environmental Tobacco Smoke. Environmental Science & Technology, 1995, 29, 2311-2316. | 10.0 | 38 |
| 219 | Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.. Journal of Clinical Oncology, 1994, 12, 1561-1571. | 1.6 | 125 |
| 220 | Murine and humanized constructs of monoclonal antibody m195 (anti-cd33) for the therapy of acute myelogenous leukemia. Cancer, 1994, 73, 1049-1056. | 4.1 | 43 |
| 221 | Overview of clinical radioimmunodetection of human tumors. Cancer, 1994, 73, 832-835. | 4.1 | 13 |
| 222 | Advances in imaging. Seminars in Oncology, 1994, 21, 598-606. | 2.2 | 2 |
| 223 | Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. Journal of Neuro-Oncology, 1993, 15, 235-242. | 2.9 | 4 |
| 224 | Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors. Acta OncolÃ³gica, 1993, 32, 709-715. | 1.8 | 14 |
| 225 | PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. Journal of Nuclear Medicine, 1992, 33, 2020-3. | 5.0 | 79 |
| 226 | Radioimmunology. Imaging and therapy. Cancer, 1991, 67, 1253-1260. | 4.1 | 47 |
| 227 | Improved Tumor Targeting With Radiolabeled, Recombinant, Single-Chain, Antigen-Binding Protein. Journal of the National Cancer Institute, 1990, 82, 1173-1174. | 6.3 | 17 |
| 228 | Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Research, 1990, 50, 892s-898s. | 0.9 | 33 |
| 229 | Long-term Effects of Local Irradiation of the Marrow on Erythron and Red Cell Function. Blood, 1970, 36, 617-622. | 1.4 | 24 |
| 230 | Long-term effects of local irradiation of the marrow on erythron and red cell function. Blood, 1970, 36, 617-22. | 1.4 | 2 |
| 231 | Distribution of the erythron and the RES in the bone marrow organ. Journal of Nuclear Medicine, 1967, 8, 430-6. | 5.0 | 18 |
| 232 | Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. Journal of Nuclear Medicine, 1966, 7, 817-26. | 5.0 | 59 |